Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Assess Bronchodilator Effect QVM149 Dosed Either in the Morning or Evening Compared to Placebo in Patients With Asthma

Phase 2

Completed

Conditions: Asthma

First Posted Date: 2017-04-11

Last Posted Date: 2021-01-05

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 38

Registration Number: NCT03108027

Locations: 🇬🇧
Novartis Investigative Site, Machester, United Kingdom

Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs

Phase 3

Active, not recruiting

Conditions: Chronic Myelogenous Leukemia

Interventions: Drug: Asciminib
Drug: Bosutinib

First Posted Date: 2017-04-10

Last Posted Date: 2024-12-27

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 233

Registration Number: NCT03106779

Locations: 🇺🇸
Indiana Blood and Marrow Institute, Beech Grove, Indiana, United States
🇺🇸
University of Michigan Clinical Trials Office, Ann Arbor, Michigan, United States
🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

and more 8 locations

A Study to Evaluate the Change in Weight After 24 Weeks Treatment With LIK066 in Obese or Overweight Adults

Phase 2

Completed

Conditions: Obesity
Overweight

Interventions: Drug: Placebo
Drug: LIK066

First Posted Date: 2017-04-04

Last Posted Date: 2020-02-06

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 460

Registration Number: NCT03100058

Locations: 🇬🇧
Novartis Investigative Site, Stevenage, United Kingdom

A Long-term Safety Study of QVM149 in Japanese Patients With Asthma

Phase 3

Completed

Conditions: Asthma

Interventions: Drug: QVM149

First Posted Date: 2017-04-04

Last Posted Date: 2020-04-07

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 96

Registration Number: NCT03100825

Locations: 🇯🇵
Novartis Investigative Site, Toshima ku, Tokyo, Japan

A Long-term Safety Study of QMF149 in Japanese Participants With Asthma

Phase 3

Completed

Conditions: Asthma

Interventions: Drug: QMF149

First Posted Date: 2017-04-04

Last Posted Date: 2020-02-07

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 51

Registration Number: NCT03100500

Locations: 🇯🇵
Novartis Investigative Site, Toshima-ku, Tokyo, Japan

Study for Women and Men With Hormone-receptor Positive Locally Advanced or Metastatic Breast Cancer

Phase 3

Completed

Conditions: Advanced Metastatic Breast Cancer

Interventions: Drug: ribociclib
Drug: letrozole
Drug: goserelin

First Posted Date: 2017-03-30

Last Posted Date: 2021-10-11

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 502

Registration Number: NCT03096847

Locations: 🇩🇪
Novartis Investigative Site, Wuerzburg, Germany

A Study Evaluating the Effectiveness of AMG 334 Injection in Preventing Migraines in Adults Having Failed Other Therapies

Phase 3

Completed

Conditions: Episodic Migraine

Interventions: Biological: AMG334 (70 mg) Pre-Filled Syringe (PFS)
Biological: Placebo Pre-Filled Syringe (PFS)

First Posted Date: 2017-03-30

Last Posted Date: 2022-03-23

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 246

Registration Number: NCT03096834

Locations: 🇬🇧
Novartis Investigative Site, London, United Kingdom

Dose Response Study of EMA401 in Patients With Post-herpetic Neuralgia (PHN)

Phase 2

Terminated

Conditions: Post-herpetic Neuralgia

Interventions: Drug: EMA401
Drug: Placebo

First Posted Date: 2017-03-29

Last Posted Date: 2021-10-08

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 130

Registration Number: NCT03094195

Locations: 🇬🇧
Novartis Investigative Site, Liverpool, United Kingdom

Pharmacokinetics and Safety of Fevipiprant in Patients With Renal Impairment Compared to Matched Healthy Subjects

Phase 1

Completed

Conditions: Renal Insufficiency

Interventions: Drug: QAW039
Drug: QAW39A
Drug: QAW39A2107

First Posted Date: 2017-03-23

Last Posted Date: 2020-12-11

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 45

Registration Number: NCT03087942

Locations: 🇩🇪
Novartis Investigative Site, Grunstadt, Germany

Phase Ib Study of PDR001 in Combination With Regorafenib in Adult Patients With Previously Treated Metastatic Colorectal Cancer

Phase 1

Completed

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: spartalizumab (PDR001)
Drug: regorafenib

First Posted Date: 2017-03-16

Last Posted Date: 2020-12-11

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 10

Registration Number: NCT03081494

Locations: 🇪🇸
Novartis Investigative Site, Madrid, Spain

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy